195 related articles for article (PubMed ID: 31293583)
1. Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions.
Sody S; Uddin M; Grüneboom A; Görgens A; Giebel B; Gunzer M; Brandau S
Front Immunol; 2019; 10():1419. PubMed ID: 31293583
[TBL] [Abstract][Full Text] [Related]
2. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Watz H; Uddin M; Pedersen F; Kirsten A; Goldmann T; Stellmacher F; Groth E; Larsson B; Böttcher G; Malmgren A; Kraan M; Rabe KF
Pulm Pharmacol Ther; 2017 Aug; 45():121-123. PubMed ID: 28549850
[No Abstract] [Full Text] [Related]
3. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
4. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
[TBL] [Abstract][Full Text] [Related]
5. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Tazzyman S; Barry ST; Ashton S; Wood P; Blakey D; Lewis CE; Murdoch C
Int J Cancer; 2011 Aug; 129(4):847-58. PubMed ID: 21328342
[TBL] [Abstract][Full Text] [Related]
7. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β.
Jablonska J; Wu CF; Andzinski L; Leschner S; Weiss S
Int J Cancer; 2014 Mar; 134(6):1346-58. PubMed ID: 24154944
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.
Mishalian I; Bayuh R; Levy L; Zolotarov L; Michaeli J; Fridlender ZG
Cancer Immunol Immunother; 2013 Nov; 62(11):1745-56. PubMed ID: 24092389
[TBL] [Abstract][Full Text] [Related]
9. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.
Andzinski L; Kasnitz N; Stahnke S; Wu CF; Gereke M; von Köckritz-Blickwede M; Schilling B; Brandau S; Weiss S; Jablonska J
Int J Cancer; 2016 Apr; 138(8):1982-93. PubMed ID: 26619320
[TBL] [Abstract][Full Text] [Related]
10. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
Uddin M; Betts C; Robinson I; Malmgren A; Humfrey C
Haematologica; 2017 Feb; 102(2):e65-e68. PubMed ID: 27742769
[No Abstract] [Full Text] [Related]
11. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
12. A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy.
Shao S; Delk NA; Jones CN
Sci Rep; 2024 Jun; 14(1):14142. PubMed ID: 38898176
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated neutrophils: friend or foe?
Fridlender ZG; Albelda SM
Carcinogenesis; 2012 May; 33(5):949-55. PubMed ID: 22425643
[TBL] [Abstract][Full Text] [Related]
14. TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2
Yu PF; Huang Y; Han YY; Lin LY; Sun WH; Rabson AB; Wang Y; Shi YF
Oncogene; 2017 Jan; 36(4):482-490. PubMed ID: 27375023
[TBL] [Abstract][Full Text] [Related]
15. A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice.
Matzer SP; Zombou J; Sarau HM; Röllinghoff M; Beuscher HU
Immunobiology; 2004; 209(3):225-33. PubMed ID: 15518334
[TBL] [Abstract][Full Text] [Related]
16. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
[TBL] [Abstract][Full Text] [Related]
17. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
[TBL] [Abstract][Full Text] [Related]
18. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells.
Moses K; Brandau S
Semin Immunol; 2016 Apr; 28(2):187-96. PubMed ID: 27067179
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy.
Chu D; Zhao Q; Yu J; Zhang F; Zhang H; Wang Z
Adv Healthc Mater; 2016 May; 5(9):1088-93. PubMed ID: 26989887
[TBL] [Abstract][Full Text] [Related]
20. Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression.
Wezel A; Lagraauw HM; van der Velden D; de Jager SC; Quax PH; Kuiper J; Bot I
Atherosclerosis; 2015 Aug; 241(2):289-96. PubMed ID: 26062988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
